MiMedx Group (NASDAQ:MDXG) versus Arbutus Biopharma (NASDAQ:ABUS) Head to Head Survey

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and MiMedx Group (NASDAQ:MDXG – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Arbutus Biopharma and MiMedx Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arbutus Biopharma 121.17% 129.12% 89.26%
MiMedx Group -6.32% 2.39% 1.85%

Analyst Recommendations

This is a breakdown of recent ratings for Arbutus Biopharma and MiMedx Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma 0 1 0 0 2.00
MiMedx Group 1 0 6 0 2.71

MiMedx Group has a consensus target price of $8.14, indicating a potential upside of 153.67%. Given MiMedx Group’s stronger consensus rating and higher possible upside, analysts plainly believe MiMedx Group is more favorable than Arbutus Biopharma.

Valuation and Earnings

This table compares Arbutus Biopharma and MiMedx Group”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arbutus Biopharma $181.49 million 3.45 -$33.50 million $1.13 3.62
MiMedx Group $418.63 million 1.12 $48.58 million ($0.13) -24.69

MiMedx Group has higher revenue and earnings than Arbutus Biopharma. MiMedx Group is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Arbutus Biopharma has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

About Arbutus Biopharma

(Get Free Report)

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development.

About MiMedx Group

(Get Free Report)

MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company’s products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.